NCT05653752 - A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Non Small Cell Lung CancerBreast Cancer

Interventions

DRUG

YL202

"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."

Trial Locations (13)

22031

Next Oncology-Virginia, Fairfax

33322

BRCR Global, Plantation

48201

Karmanos Cancer Institute, Detroit

75039

Next Oncology-Dallas, Irving

75701

UT health east Texas HOPE Cancer Center, Tyler

77030

The University of Texas MD Anderson Cancer Center, Houston

99216

Summit Cancer Center, Spokane Valley

130012

Jilin Provincial Cancer Hospital, Changchun

310003

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

317099

Taizhou Hospital of Zhejiang Province, Taizhou

350014

Fujian Cancer Hospital, Fuzhou

410013

Hunan Cancer Hospital, Changsha